Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas

[1]  T. Dønnem,et al.  Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas , 2012, PloS one.

[2]  Chia-Hsin Chan,et al.  Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis , 2012, Chinese journal of cancer.

[3]  T. Dønnem,et al.  The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas , 2011, Journal of Translational Medicine.

[4]  Jen-kun Lin,et al.  1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. , 2011, Journal of agricultural and food chemistry.

[5]  T. Dønnem,et al.  Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. , 2011, International journal of oncology.

[6]  T. Dønnem,et al.  The Prognostic Impact of TGF-β1, Fascin, NF-κB and PKC-ζ Expression in Soft Tissue Sarcomas , 2011, PloS one.

[7]  T. Nielsen,et al.  The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. , 2008, Human pathology.

[8]  Chien-Feng Li,et al.  Flow Cytometric Analysis of DNA Ploidy and S-Phase Fraction in Primary Localized Myxofibrosarcoma: Correlations with Clinicopathological Factors, Skp2 Expression, and Patient Survival , 2008, Annals of Surgical Oncology.

[9]  F. Demichelis,et al.  Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours , 2008, BMC Cancer.

[10]  Hsuan-Ying Huang,et al.  Skp2 Overexpression Is Highly Representative of Intrinsic Biological Aggressiveness and Independently Associated with Poor Prognosis in Primary Localized Myxofibrosarcomas , 2006, Clinical Cancer Research.

[11]  Jian-ming Zheng,et al.  Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy , 2005, Steroids.

[12]  J. Goldblum,et al.  Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas: An Immunohistochemical Study , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  R. Lloyd,et al.  Skp2 protein expression in soft tissue sarcomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Ramaswamy,et al.  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. , 2002, The Journal of clinical investigation.

[15]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[16]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[17]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Asselain,et al.  Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome , 1998, Breast Cancer Research and Treatment.

[19]  C. Redmond,et al.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Redmond,et al.  Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.

[21]  E. J. Gregory,et al.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.

[22]  C. Beattie,et al.  Distribution of steroid hormone receptors in human soft tissue sarcomas. , 1981, Surgery.